X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs LUPIN LTD - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD LUPIN LTD ORCHID PHARMA LTD/
LUPIN LTD
 
P/E (TTM) x -0.6 23.2 - View Chart
P/BV x 0.4 3.1 14.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ORCHID PHARMA LTD   LUPIN LTD
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
LUPIN LTD
Mar-17
ORCHID PHARMA LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1941,750 11.1%   
Low Rs351,384 2.5%   
Sales per share (Unadj.) Rs276.5387.4 71.4%  
Earnings per share (Unadj.) Rs-79.256.6 -139.9%  
Cash flow per share (Unadj.) Rs-43.576.8 -56.6%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9298.9 18.0%  
Shares outstanding (eoy) m70.45451.58 15.6%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x0.44.0 10.2%   
Avg P/E ratio x-1.427.7 -5.2%  
P/CF ratio (eoy) x-2.620.4 -12.9%  
Price / Book Value ratio x2.15.2 40.5%  
Dividend payout %013.2 0.0%   
Avg Mkt Cap Rs m8,067707,513 1.1%   
No. of employees `0002.816.8 16.7%   
Total wages/salary Rs m2,52728,495 8.9%   
Avg. sales/employee Rs Th6,956.110,418.3 66.8%   
Avg. wages/employee Rs Th902.51,697.0 53.2%   
Avg. net profit/employee Rs Th-1,993.01,523.0 -130.9%   
INCOME DATA
Net Sales Rs m19,477174,943 11.1%  
Other income Rs m4071,065 38.2%   
Total revenues Rs m19,884176,008 11.3%   
Gross profit Rs m1,10344,931 2.5%  
Depreciation Rs m2,5199,122 27.6%   
Interest Rs m5,2271,525 342.7%   
Profit before tax Rs m-6,23635,349 -17.6%   
Minority Interest Rs m20-72 -27.5%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1259,785 -1.3%   
Profit after tax Rs m-5,58025,575 -21.8%  
Gross profit margin %5.725.7 22.0%  
Effective tax rate %2.027.7 7.3%   
Net profit margin %-28.714.6 -196.0%  
BALANCE SHEET DATA
Current assets Rs m11,014119,542 9.2%   
Current liabilities Rs m32,06061,206 52.4%   
Net working cap to sales %-108.133.3 -324.0%  
Current ratio x0.32.0 17.6%  
Inventory Days Days9576 124.8%  
Debtors Days Days3490 37.3%  
Net fixed assets Rs m29,440131,660 22.4%   
Share capital Rs m705903 78.0%   
"Free" reserves Rs m2,043134,073 1.5%   
Net worth Rs m3,800134,976 2.8%   
Long term debt Rs m9,01856,478 16.0%   
Total assets Rs m46,510266,073 17.5%  
Interest coverage x-0.224.2 -0.8%   
Debt to equity ratio x2.40.4 567.2%  
Sales to assets ratio x0.40.7 63.7%   
Return on assets %-0.810.2 -7.5%  
Return on equity %-146.918.9 -775.1%  
Return on capital %-3.719.3 -19.4%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51381,885 9.2%   
Fx outflow Rs m5,64921,506 26.3%   
Net fx Rs m1,86560,378 3.1%   
CASH FLOW
From Operations Rs m1,68241,148 4.1%  
From Investments Rs m-9,860-25,287 39.0%  
From Financial Activity Rs m6,6444,332 153.4%  
Net Cashflow Rs m-1,53520,193 -7.6%  

Share Holding

Indian Promoters % 32.3 46.6 69.3%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 31.9 10.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.1 547.5%  
Shareholders   84,811 98,259 86.3%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jan 23, 2018 11:19 AM

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - SUVEN LIFE COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS